Summa Biotech is a medical biotech company that was founded in 2022 and focuses on developing ground-breaking RNA medicine to reverse the damage of ischemic heart disease. Our purpose: “The neglected heart regenerated” by restoring damaged heart tissue through eliciting regeneration of healthy cells and tissues using RNA therapeutics.
We focus on:
- revolutionary RNA-based therapies capable of regenerating the human heart from within.
- precise targeting and controlled modulation of genetic pathways involved in heart muscle cell renewal and tissue repair.
- advanced laboratory models of heart disease that accurately replicate key features of (ischemic) heart conditions.
